213 related articles for article (PubMed ID: 21855120)
1. Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis.
Vay A; Kumar S; Seward S; Semaan A; Schiffer CA; Munkarah AR; Morris RT
Gynecol Oncol; 2011 Dec; 123(3):456-60. PubMed ID: 21855120
[TBL] [Abstract][Full Text] [Related]
2. Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
Sedeta E; Jemal A; Nisotel L; Sung H
Cancer; 2024 Jun; 130(11):1952-1963. PubMed ID: 38244208
[TBL] [Abstract][Full Text] [Related]
3. Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosis.
Giri S; Chi M; Johnson B; McCormick D; Jamy O; Bhatt VR; Martin MG
Leuk Res; 2015 Dec; 39(12):1342-6. PubMed ID: 26427729
[TBL] [Abstract][Full Text] [Related]
4. Histological Tumor Type is Associated with One-Year Cause-Specific Survival in Women with Stage III-IV Epithelial Ovarian Cancer: A Surveillance, Epidemiology, and End Results (SEER) Database Population Study, 2004-2014.
Wu SG; Li FY; Lei J; Hua L; He ZY; Zhou J
Med Sci Monit; 2020 Feb; 26():e920531. PubMed ID: 32008036
[TBL] [Abstract][Full Text] [Related]
5. Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients.
Sehouli J; Fotopoulou C; Erol E; Richter R; Reuss A; Mahner S; Lauraine EP; Kristensen G; Herrstedt J; du Bois A; Pfisterer J
Eur J Cancer; 2015 May; 51(7):825-32. PubMed ID: 25771433
[TBL] [Abstract][Full Text] [Related]
6. Acute Myeloid Leukemia Following Gynecologic Cancer in the Era of Platinum-Based Chemotherapy.
Nasioudis D; Lontos K; Tsagianni A; Boyiadzis M; Ko EM
Int J Gynecol Cancer; 2018 Oct; 28(8):1639-1642. PubMed ID: 30095705
[TBL] [Abstract][Full Text] [Related]
7. The "luxury" of second malignancies.
Armstrong DK; Visvanathan K
Gynecol Oncol; 2011 Dec; 123(3):453-4. PubMed ID: 21996261
[No Abstract] [Full Text] [Related]
8. Carcinosarcoma of the ovary: a case-control study.
Rauh-Hain JA; Growdon WB; Rodriguez N; Goodman AK; Boruta DM; Schorge JO; Horowitz NS; del Carmen MG
Gynecol Oncol; 2011 Jun; 121(3):477-81. PubMed ID: 21420726
[TBL] [Abstract][Full Text] [Related]
9. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.
Forde GK; Chang J; Ziogas A; Tewari K; Bristow RE
Gynecol Oncol; 2015 Jun; 137(3):479-84. PubMed ID: 25866323
[TBL] [Abstract][Full Text] [Related]
10. An increased risk of epithelial ovarian cancer in Taiwanese women with a new surgico-pathological diagnosis of endometriosis.
Wang KC; Chang WH; Lee WL; Huang N; Huang HY; Yen MS; Guo CY; Wang PH
BMC Cancer; 2014 Nov; 14():831. PubMed ID: 25403543
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of marital status on survival of women with epithelial ovarian cancer.
Mahdi H; Kumar S; Munkarah AR; Abdalamir M; Doherty M; Swensen R
Psychooncology; 2013 Jan; 22(1):83-8. PubMed ID: 21919121
[TBL] [Abstract][Full Text] [Related]
12. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
Miao Y; Yan Q; Li S; Li B; Feng Y
Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
[TBL] [Abstract][Full Text] [Related]
14. Metformin intake is associated with better survival in ovarian cancer: a case-control study.
Kumar S; Meuter A; Thapa P; Langstraat C; Giri S; Chien J; Rattan R; Cliby W; Shridhar V
Cancer; 2013 Feb; 119(3):555-62. PubMed ID: 23208739
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
16. Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis.
Vogel TJ; Jeon C; Karlan B; Walsh C
Gynecol Oncol; 2016 Feb; 140(2):285-8. PubMed ID: 26691221
[TBL] [Abstract][Full Text] [Related]
17. A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer.
Xu XL; Cheng H; Tang MS; Zhang HL; Wu RY; Yu Y; Li X; Wang XM; Mai J; Yang CL; Jiao L; Li ZL; Zhong ZM; Deng R; Li JD; Zhu XF
Oncotarget; 2017 Jan; 8(5):8120-8130. PubMed ID: 28042955
[TBL] [Abstract][Full Text] [Related]
18. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
19. Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer.
Joseph N; Clark RM; Dizon DS; Lee MS; Goodman A; Boruta D; Schorge JO; Del Carmen MG; Growdon WB
Gynecol Oncol; 2015 Jun; 137(3):401-5. PubMed ID: 25839911
[TBL] [Abstract][Full Text] [Related]
20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
